Neurocrine Biosciences’ experimental drug, NBI-1117568, demonstrated positive results in a Phase 2 clinical trial for schizophrenia, showing a significant reduction in symptoms compared to placebo. The drug’s potential as a safer alternative to atypical antipsychotics has sparked optimism among analysts, leading to an upgrade in the company’s stock.
Results for: NBI-1117568
Neurocrine Biosciences’ experimental schizophrenia drug, NBI-1117568, demonstrated a statistically significant improvement in symptoms in a Phase 2 clinical trial, but the effect size was lower than some competing treatments. The company’s stock price dropped significantly following the news.